Evidence of Priority to Provisional Application and that Prior Art Was Not Work of Another Defeated Obviousness Challenge in IPR

Apr 6, 2017

Reading Time : 2 min

Every claim in the ’703 Patent requires treatment with the composition for at least two weeks. The ’703 Patent’s corresponding provisional application described a treatment regimen with fampridine that included a two-week upward titration to reach a certain dosage followed by 12 weeks of stable treatment at that dosage. Certain of the claims also require an average steady state plasma concentration (“CavSS”) of the drug within a certain range. The provisional application reported the CavSS levels for treatment using a 10 mg dosage of the drug.

Petitioner argued that disclosure of a 12-week treatment does not specifically teach treatment for two weeks and that there would always be two different concentrations used during the two-week titration period disclosed in the provisional application. Petitioner also argued that the provisional application failed to teach the entire claimed CavSS range. In response, Acorda’s experts explained that there would be no change in dosage during the two-week titration period that corresponded to stable treatment using the lowest dose (10 mg). Moreover, one of skill would consider the standard deviation of reported CavSS values and would understand that the application discloses CavSS values across the entire claimed range. Acorda also introduced declarations from inventors and noninventors indicating that the cited portions of S-1 were the inventors’ own work.

The Board credited Acorda’s experts’ testimony related to the lowest-dose treatment and concluded that the provisional application supported the “two-week limitations” of the ’703 Patent claims. The Board also agreed that one of skill would consider the standard deviation and would have understood the provisional application to disclose the claimed CavSS range. Accordingly, the Board concluded that all claims of the ’703 Patent were entitled to the priority date of the provisional application and that the S-1 reference was therefore not 102(b) prior art to any claim in the IPR.

The Board next considered whether the S-1 reference was the work of others. The Board concluded that Petitioner met its initial burden by presenting S-1 as prior art that, on its face, lists authors that differ from the inventors. However, Acorda responded with declarations indicating that the inventors were the sole source of the cited portions of S-1, satisfying its burden of production to refute Petitioner’s argument. Petitioner’s reply did not persuade the Board that S-1 was not solely attributable to the named inventors. Thus, the Board held that S-1 was not “work by others” and could not qualify as prior art under 102(a). S-1 was therefore not prior art to any claim in the IPR. Because all potential obviousness grounds included S-1, the Board held that Petitioner failed to prove the claims of the ’703 Patent unpatentable as obvious.

Finally, the Board noted that the patents challenged in three related IPR proceedings (IPR2015-01853, IPR2015-01857 and IPR2015-01858) included similar claims. The Board applied its analysis to the claims in those proceedings and, in each case, determined that Petitioner failed to meet its burden to prove those claims unpatentable. The Board’s Final Written Decision therefore resolved those related IPRs.

Coalition for Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc. IPR2015-01850, IPR2015-01853, IPR2015-01857, IPR2015-01858, Paper No. 72 (PTAB Mar. 9, 2017).

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.